1. Home
  2. CUZ vs CRSP Comparison

CUZ vs CRSP Comparison

Compare CUZ & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUZ
  • CRSP
  • Stock Information
  • Founded
  • CUZ 1958
  • CRSP 2013
  • Country
  • CUZ United States
  • CRSP Switzerland
  • Employees
  • CUZ N/A
  • CRSP N/A
  • Industry
  • CUZ Real Estate Investment Trusts
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CUZ Real Estate
  • CRSP Health Care
  • Exchange
  • CUZ Nasdaq
  • CRSP Nasdaq
  • Market Cap
  • CUZ 5.0B
  • CRSP 4.9B
  • IPO Year
  • CUZ N/A
  • CRSP 2016
  • Fundamental
  • Price
  • CUZ $29.49
  • CRSP $56.03
  • Analyst Decision
  • CUZ Buy
  • CRSP Buy
  • Analyst Count
  • CUZ 9
  • CRSP 16
  • Target Price
  • CUZ $32.22
  • CRSP $72.27
  • AVG Volume (30 Days)
  • CUZ 1.5M
  • CRSP 2.0M
  • Earning Date
  • CUZ 10-23-2025
  • CRSP 11-04-2025
  • Dividend Yield
  • CUZ 4.32%
  • CRSP N/A
  • EPS Growth
  • CUZ N/A
  • CRSP N/A
  • EPS
  • CUZ 0.37
  • CRSP N/A
  • Revenue
  • CUZ $917,942,000.00
  • CRSP $38,050,000.00
  • Revenue This Year
  • CUZ $13.63
  • CRSP $11.17
  • Revenue Next Year
  • CUZ $3.36
  • CRSP $296.09
  • P/E Ratio
  • CUZ $79.81
  • CRSP N/A
  • Revenue Growth
  • CUZ 11.98
  • CRSP N/A
  • 52 Week Low
  • CUZ $24.07
  • CRSP $30.04
  • 52 Week High
  • CUZ $32.55
  • CRSP $71.13
  • Technical
  • Relative Strength Index (RSI)
  • CUZ 61.39
  • CRSP 54.68
  • Support Level
  • CUZ $28.61
  • CRSP $51.63
  • Resistance Level
  • CUZ $29.82
  • CRSP $55.59
  • Average True Range (ATR)
  • CUZ 0.54
  • CRSP 2.06
  • MACD
  • CUZ 0.08
  • CRSP 0.27
  • Stochastic Oscillator
  • CUZ 87.29
  • CRSP 96.50

About CUZ Cousins Properties Incorporated

Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: